Biologics Market Size, Share, Growth, and Industry Analysis, By Type (Monoclonal Antibodies,Vaccines,Recombinant Hormones/Proteins,Cellular Based Biologics,Gene Based Biologics), By Application (Oncology,Infectious Diseases,Immunology,Autoimmune Diseases), Regional Insights and Forecast to 2035

Biologics Market Overview

The global Biologics Market is forecast to expand from USD 341422.89 million in 2026 to USD 373619.07 million in 2027, and is expected to reach USD 768340.91 million by 2035, growing at a CAGR of 9.43% over the forecast period.

The Biologics Market Report highlights that as of 2024, over 120 monoclonal antibody therapies are approved worldwide, with more than 60 biosimilars authorized, and upwards of 500 antibody candidates undergoing clinical trials.

In the USA, the Biologics Market Size includes more than 300 FDA-approved biologics, including over 60 biosimilars, supported by more than 2,000 ongoing clinical trials. The US houses approximately 400 biologics manufacturing facilities and employs over 50,000 professionals in R&D and bioproduction.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: The Biologics Market Trends show that 60 percent of drug pipelines are biologics, 45 percent of funding is directed to monoclonal antibody R&D, and 30 percent to gene-based biologics.
• Major Market Restraint: The Biologics Market Analysis indicates high manufacturing cost deters 55 percent of startups, pricing concerns impact 35 percent of payers, and regulatory complexity slows 25 percent of approvals.
• Emerging Trends: The Biologics Market Insights identify that 50 percent of launches are biosimilars, 30 percent involve bispecific antibodies, and 20 percent include cell or gene therapies.
• Regional Leadership: The Biologics Market Share reflects North America at 35 percent, Europe 25 percent, Asia-Pacific 30 percent, Middle East & Africa 10 percent of installations or manufacturing capacity.
• Competitive Landscape: The Biologics Market Forecast shows top two firms hold 45 percent of product approvals, next three firms 30 percent, and others 25 percent.
• Market Segmentation: The Biologics Market Segmentation shows monoclonal antibodies 40 percent, vaccines 25 percent, recombinant proteins 15 percent, cellular/gene-based biologics 20 percent by approvals.
• Recent Development: The Biologics Market Research Report notes new approvals this year include 12 mAbs, 5 vaccines, and 2 gene therapies, while 40 biosimilars entered development programs.

Biologics Market Latest Trends

The Biologics Market Latest Trends spotlight rapid shifts in therapy formats and regulatory patterns across 2024–2025. This year, over 120 monoclonal antibodies are approved globally, while biosimilars expanded to 60+ approvals, showing a growing competitive landscape. Of newly approved drugs in 2023, 17 biologics represented 30 percent of total drug approvals—a rate consistent with earlier years and signaling sustained biologic momentum.

Biologics Market Dynamics

The Biologics Market Analysis reveals a dynamic interplay of growth drivers, restraints, opportunities, and challenges that shape competitive strategies across the global biologics landscape. Over 60 percent of active drug development pipelines now involve biologics, with monoclonal antibodies alone representing 40 percent of newly approved therapies in the past two years.

DRIVER

"Expansion of therapeutic modalities and biosimilar competition"

The DRIVER in the biologics market is the growing expansion into diverse therapeutic modalities and biosimilar development. Since 2022, 500+ mAb candidates are in active development, with 30 percent specifically targeting oncology and immunology, and 20 percent focused on rare diseases.

RESTRAINT

"High development complexity and limited biosimilar penetration"

The RESTRAINT lies in complexity and limited biosimilar penetration. Even though 60 biosimilars are approved, only 50 percent have launched commercially, reflecting market hesitancy. Regulatory complexity affects 40 percent of manufacturing scale-ups, and pricing scrutiny affects 35 percent of biologic launches.

OPPORTUNITY

"Bispecifics, gene therapies, and emerging markets"

The OPPORTUNITY lies in bispecific constructs, gene therapies, and emerging market expansion. As of 2025, 20 percent of new mAb approvals include bispecific antibodies like mosunetuzumab and linvoseltamab. Gene therapies now represent 10 percent of biologic approvals, signaling novel treatment paradigms.

CHALLENGE

"Regulatory complexities and pricing pressure"

The CHALLENGE comes from regulatory hurdles and pricing pressure. The FDA approved 55 new drugs in 2023, including 17 biologics, but regulatory breakdown shows only 5 biosimilars granted interchangeability status out of 60+ approvals, underscoring approval bottlenecks.

Biologics Market Segmentation

The Biologics Market Segmentation divides therapies by type and application: monoclonal antibodies account for 40 percent, vaccines 25 percent, recombinant proteins 15 percent, cellular/gene biologics 20 percent. In application areas, oncology leads at 35 percent of usage volume, followed by immunology 25 percent, infectious diseases 20 percent, and autoimmune disorders 20 percent.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Monoclonal Antibodies: Monoclonal Antibodies (mAbs) represent approximately 40 percent of the Biologics Market. There are over 120 approved mAb therapies globally, and 500+ mAb candidates in clinical development.

The monoclonal antibodies segment is projected to account for approximately USD 124,800 million in 2025, representing around 40% of the global biologics market valued at USD 312,001.17 million, and is anticipated to expand consistently at a CAGR of 9.43% over the forecast period.

Top 5 Major Dominant Countries in the Monoclonal Antibodies Segment

• United States: The United States commands an estimated USD 49,920 million in 2025 within the monoclonal antibodies segment, securing 40% of the global share in this category, supported by advanced biopharmaceutical manufacturing and leading clinical trial infrastructure, with growth at 9.43% annually.
• China: China is projected to achieve approximately USD 24,960 million in 2025, accounting for 20% of the segment’s share, driven by rapid biologics adoption in oncology and autoimmune disease therapies, maintaining an annual growth pace of 9.43%.
• Germany: Germany secures about USD 18,720 million in 2025, translating to 15% of the segment’s share, benefitting from robust R&D investment and established biomanufacturing clusters, with steady growth of 9.43% annually.
• Japan: Japan is expected to reach USD 12,480 million in 2025, capturing 10% of the market share within monoclonal antibodies, boosted by advanced healthcare infrastructure and rising biologic therapy penetration, with an annual growth rate of 9.43%.
• United Kingdom: The United Kingdom will hold roughly USD 9,984 million in 2025, about 8% of the market share, supported by innovation-driven biotech hubs and strong regulatory support for biologic drug approvals, expanding at 9.43% annually.

Vaccines: Vaccines account for about 25 percent of the biologics segment. In 2023, 5 new biologic vaccines were approved, adding to over 200 existing biologic vaccine products. COVID-19 platforms still account for 20 percent of vaccine volumes, with oncology vaccines rising at 10 percent share.

The Vaccines segment is expected to account for nearly USD 84,240 million in 2025, comprising about 27% share of the global biologics market, with a projected CAGR of 9.43% through 2034, supported by rising immunization programs and technological advancements in vaccine platforms.

Top 5 Major Dominant Countries in the Vaccines Segment

• United States: The United States vaccine market is projected to reach USD 33,696 million in 2025, commanding approximately 40% share and a CAGR of 9.43%, driven by strong governmental funding and continuous innovation in preventive healthcare solutions.
• China: China’s vaccines segment is forecasted at USD 16,848 million in 2025, securing about 20% share with a CAGR of 9.43%, fueled by extensive domestic vaccine production capacity and increasing public health awareness initiatives.
• India: India is anticipated to achieve USD 8,424 million in vaccine market value by 2025, capturing nearly 10% share and a CAGR of 9.43%, supported by expanding immunization coverage and competitive manufacturing capabilities.
• Germany: Germany’s vaccines market will be valued at USD 6,739 million in 2025, representing about 8% share and a CAGR of 9.43%, reflecting advanced biotechnology infrastructure and strong adoption of next-generation vaccine technologies.
• Brazil: Brazil is expected to hold USD 5,897 million in vaccine market size in 2025, corresponding to 7% share with a CAGR of 9.43%, driven by robust public healthcare vaccination programs and increasing demand for imported biologic vaccines.

Recombinant Hormones/Proteins: Recombinant Hormones and Proteins represent 15 percent of the biologics market. There are approximately 150 recombinant protein products approved globally, comprising insulin analogs, growth factors, and clotting factors.

The Recombinant Hormones/Proteins segment will account for approximately USD 62,400 million in 2025, representing around 20% share of the biologics market, and is forecasted to grow at a CAGR of 9.43%, supported by high demand in endocrine and metabolic disorder treatment.

Top 5 Major Dominant Countries in the Recombinant Hormones/Proteins Segment

• United States: The United States recombinant hormones/proteins market is estimated at USD 24,960 million in 2025, representing 40% share and a CAGR of 9.43%, backed by advanced research facilities and high biologics penetration rates in therapeutic areas.
•  
• China: China will reach USD 12,480 million in recombinant hormones/proteins market value by 2025, with 20% share and a CAGR of 9.43%, driven by cost-efficient production and rising prevalence of hormone-related disorders.
• Japan: Japan’s recombinant hormones/proteins market size is projected at USD 6,240 million in 2025, holding 10% share with a CAGR of 9.43%, due to strong investment in protein engineering and advanced therapeutic applications.
• Germany: Germany is expected to secure USD 4,992 million in this segment in 2025, making up 8% share and a CAGR of 9.43%, reflecting its robust biomanufacturing infrastructure and high adoption in clinical settings.
• India: India’s recombinant hormones/proteins market is projected at USD 4,368 million in 2025, accounting for 7% share and a CAGR of 9.43%, fueled by growing export demand and expansion in biologics production capacity.

Cellular Based Biologics: Cellular Based Biologics, including CAR-T therapies and stem cell products, make up about 10 percent of the biologics portfolio. There are currently over 50 CAR-T products approved or in late-stage trials, and 70+ stem cell biologics under investigation. This year saw 2 new cellular therapy approvals.

The Cellular Based Biologics segment will account for nearly USD 37,440 million in 2025, securing 12% share of the global biologics market, with a projected CAGR of 9.43% through 2034, driven by advancements in regenerative medicine and personalized therapies.

Top 5 Major Dominant Countries in the Cellular Based Biologics Segment

• United States: The United States cellular biologics market is anticipated at USD 14,976 million in 2025, achieving 40% share and a CAGR of 9.43%, powered by strong investments in stem cell research and therapy commercialization.
• China: China will hold USD 7,488 million in market value for cellular biologics in 2025, representing 20% share and a CAGR of 9.43%, benefiting from growing biotech start-ups and government-backed cell therapy projects.
• Japan: Japan is projected to account for USD 3,744 million in cellular biologics in 2025, representing 10% share and a CAGR of 9.43%, leveraging advancements in iPSC technology and cutting-edge regenerative medicine research.
• Germany: Germany’s market for cellular biologics is forecasted at USD 2,995 million in 2025, corresponding to 8% share and a CAGR of 9.43%, strengthened by favorable regulations and well-established clinical trial frameworks.
• South Korea: South Korea is estimated at USD 2,620 million in 2025 for cellular biologics, making up 7% share and a CAGR of 9.43%, supported by rapid adoption of advanced biologic treatment technologies.

Gene Based Biologics: Gene Based Biologics, including gene therapies and viral vectors, constitute 10 percent of the biologics market. There are roughly 20 gene therapy products approved globally, with 5 new approvals in 2023. Notably, linvoseltamab bispecific antibody gained FDA approval in July 2025, adding to innovation narratives. North America leads with 8 products, Europe 6, Asia-Pacific 4, and Middle East & Africa 2 units.

The Gene Based Biologics segment is projected to be valued at USD 18,720 million in 2025, representing 6% share of the total biologics market, with a CAGR of 9.43%, driven by breakthroughs in gene therapy and genetic engineering.

Top 5 Major Dominant Countries in the Gene Based Biologics Segment

• United States: The United States is forecasted at USD 7,488 million in 2025 for gene-based biologics, with 40% share and a CAGR of 9.43%, propelled by FDA approvals and expanding gene therapy clinical pipelines.
• China: China’s gene-based biologics market will be USD 3,744 million in 2025, securing 20% share and a CAGR of 9.43%, aided by government-driven biotech investments and innovative gene therapy platforms.
• Germany: Germany is anticipated to achieve USD 1,498 million in gene-based biologics market value in 2025, capturing 8% share and a CAGR of 9.43%, benefiting from its advanced genomic research capabilities.
• Japan: Japan’s gene-based biologics market will reach USD 1,872 million in 2025, corresponding to 10% share and a CAGR of 9.43%, boosted by high demand for rare disease gene therapy treatments.
• United Kingdom: The United Kingdom is projected at USD 1,310 million in gene-based biologics in 2025, representing 7% share and a CAGR of 9.43%, driven by cutting-edge biotechnology innovation and robust clinical trial networks.

BY APPLICATION

Oncology: Oncology leads applications with 35 percent of the biologics market, including 60+ mAbs, 5 CAR-T therapies, and 3 gene therapies targeting cancer. In 2023, 10 new oncology biologics were approved. Geographically, North America leads with 40 products, Europe 25, Asia-Pacific 15, and Middle East & Africa 5 units. Key numeric drivers include PD-1 checkpoint inhibitors and bispecific antibodies.

The Oncology application segment is projected to hold approximately USD 124,800 million in 2025, representing around 40% share of the total biologics market, with a CAGR of 9.43% through 2034, driven by the surging demand for targeted cancer therapies and immuno-oncology biologics.

Top 5 Major Dominant Countries in the Oncology Application

• United States: The United States oncology biologics market is estimated to be USD 49,920 million in 2025, commanding 40% share and a CAGR of 9.43%, reflecting its leadership in clinical oncology research and biologics approvals.
• China: China will reach USD 24,960 million in oncology biologics value by 2025, holding 20% share and a CAGR of 9.43%, backed by rapid expansion in cancer care infrastructure and biologics manufacturing.
• Japan: Japan is projected at USD 12,480 million in oncology biologics in 2025, making up 10% share with a CAGR of 9.43%, supported by high adoption of biologic-based precision oncology treatments.
• Germany: Germany’s oncology biologics segment will be USD 9,984 million in 2025, capturing 8% share and a CAGR of 9.43%, with growth driven by advanced research collaborations in cancer immunotherapies.
• India: India is expected to hold USD 8,736 million in oncology biologics market size in 2025, corresponding to 7% share with a CAGR of 9.43%, supported by growing patient access to affordable biosimilar cancer biologics.

Infectious Diseases: Infectious Diseases account for 20 percent of biologic applications, including 60 vaccines, antiviral mAbs, and passive immunotherapies. In 2023, 3 new biologic infectious disease products were approved. Regional spread includes 25 in North America, 20 in Europe, 15 in Asia-Pacific, and 5 in Middle East & Africa. Notably, COVID-related biologics still represent 20 percent of usage volume.

The Infectious Diseases application segment is anticipated to account for USD 93,600 million in 2025, representing 30% share of the biologics market, with a CAGR of 9.43%, bolstered by increasing demand for biologic vaccines and antibody-based antiviral therapies.

Top 5 Major Dominant Countries in the Infectious Diseases Application

• United States: The United States market for infectious disease biologics is valued at USD 37,440 million in 2025, capturing 40% share and a CAGR of 9.43%, driven by extensive public immunization programs and novel vaccine development.
• China: China will achieve USD 18,720 million in 2025 for infectious disease biologics, securing 20% share and a CAGR of 9.43%, supported by large-scale infectious disease prevention strategies and domestic biologics innovation.
• India: India is projected at USD 9,360 million in infectious disease biologics in 2025, accounting for 10% share with a CAGR of 9.43%, boosted by cost-efficient vaccine manufacturing and broad export reach.
• Germany: Germany’s infectious disease biologics market is expected to be USD 7,488 million in 2025, representing 8% share and a CAGR of 9.43%, with growth driven by advanced biotechnology and public health initiatives.
• Brazil: Brazil will hold USD 6,552 million in 2025 for infectious disease biologics, comprising 7% share and a CAGR of 9.43%, driven by national vaccine campaigns and increasing biologics imports.

Immunology: Immunology constitutes 25 percent of biologic application areas, including anti-TNF mAbs and interleukin inhibitors. There are 50 approved immunology biologics, and 5 new approvals in 2023. Regional breakdown includes 20 in North America, 15 in Europe, 10 in Asia-Pacific, and 5 in Middle East & Africa.

The Immunology application segment will hold about USD 62,400 million in 2025, capturing 20% share of the global biologics market, with a CAGR of 9.43%, propelled by high demand for biologics treating immune system disorders and chronic inflammatory conditions.

Top 5 Major Dominant Countries in the Immunology Application

• United States: The United States immunology biologics market is projected at USD 24,960 million in 2025, with 40% share and a CAGR of 9.43%, fueled by cutting-edge R&D and advanced therapeutic adoption.
• China: China will secure USD 12,480 million in immunology biologics by 2025, representing 20% share and a CAGR of 9.43%, driven by emerging treatment pipelines for autoimmune and inflammatory diseases.
• Japan: Japan’s immunology biologics market will be USD 6,240 million in 2025, making up 10% share with a CAGR of 9.43%, supported by an aging population and strong specialty biologics adoption.
• Germany: Germany is forecasted at USD 4,992 million in 2025 for immunology biologics, with 8% share and a CAGR of 9.43%, reflecting solid clinical demand and biosimilar launches.
• United Kingdom: The United Kingdom immunology biologics market is projected at USD 4,368 million in 2025, securing 7% share and a CAGR of 9.43%, driven by advanced healthcare infrastructure and high patient access.

Autoimmune Diseases: Autoimmune Diseases account for 20 percent of biologics usage, overlapping with immunology. This includes 40 approved products, with 3 new approvals in 2023. Distribution: North America 15, Europe 10, Asia-Pacific 8, Middle East & Africa 2 units. Biologics for lupus, MS, and rare autoimmune conditions are growing.

The Autoimmune Diseases application segment is set to reach USD 31,200 million in 2025, representing 10% share of the biologics market, with a CAGR of 9.43%, fueled by rising prevalence of conditions like rheumatoid arthritis, lupus, and multiple sclerosis.

Top 5 Major Dominant Countries in the Autoimmune Diseases Application

• United States: The United States autoimmune disease biologics market is estimated at USD 12,480 million in 2025, with 40% share and a CAGR of 9.43%, backed by extensive clinical trials and novel drug approvals.
• China: China will achieve USD 6,240 million in autoimmune biologics in 2025, securing 20% share and a CAGR of 9.43%, supported by growing healthcare spending and biologics production capabilities.
• Germany: Germany’s autoimmune disease biologics market will be USD 2,496 million in 2025, representing 8% share and a CAGR of 9.43%, driven by adoption of targeted therapies.
• Japan: Japan is projected to secure USD 3,120 million in autoimmune biologics in 2025, corresponding to 10% share and a CAGR of 9.43%, aided by advanced therapeutic research.
• India: India will hold USD 2,184 million in autoimmune biologics in 2025, accounting for 7% share and a CAGR of 9.43%, fueled by increasing demand for affordable biologics treatments.

Regional Outlook for the Biologics Market

Summary: Global biologics market deployments total 917.95 million USD in value units potential. North America holds 34 percent, Europe 27 percent, Asia-Pacific 27 percent, and Middle East & Africa 12 percent.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America is set to reach approximately USD 312.10 million of biologics demand in 2025, capturing 34 percent of global market value. This region features around 300 FDA-approved biologics, comprising 40 percent mAbs, 25 percent vaccines, 15 percent recombinant proteins, and 20 percent cellular and gene therapies.

The North America biologics market is projected to hold a dominant position with an estimated USD 124,800 million in 2025, representing approximately 40% share of the total global market, supported by a strong biopharmaceutical manufacturing base, advanced clinical research infrastructure, and rapid adoption of innovative biologics across diverse therapeutic areas.

North America – Major Dominant Countries in the Biologics Market

• United States: The United States will hold USD 93,600 million in 2025, accounting for 75% share of the North American biologics market, with a CAGR of 9.43%, driven by unmatched R&D capacity and high biologics consumption rates.
• Canada: Canada’s biologics market will reach USD 18,720 million in 2025, representing 15% share and a CAGR of 9.43%, bolstered by increasing biosimilar launches and growing government healthcare expenditure.
• Mexico: Mexico will capture USD 6,240 million in 2025, about 5% share and a CAGR of 9.43%, supported by rising biologics imports and demand in private healthcare sectors.
• Puerto Rico: Puerto Rico will secure USD 3,744 million in 2025, representing 3% share and a CAGR of 9.43%, aided by its established pharmaceutical manufacturing facilities.
• Dominican Republic: The Dominican Republic will hold USD 2,496 million in 2025, equivalent to 2% share and a CAGR of 9.43%, backed by expanding distribution networks for biologics.

EUROPE

Europe’s biologics market is valued at approximately USD 247.85 million, comprising 27 percent of the global market. The region features about 150 monoclonal antibodies, 80 vaccines, 45 recombinant proteins, 25 cellular therapies, and 10 gene therapies approved or in late-stage development.

Europe is set to command a significant portion of the biologics market with USD 93,600 million in 2025, representing 30% share, driven by the region’s leadership in biosimilar development, comprehensive healthcare access, and strong clinical adoption of biologic therapies in oncology, immunology, and infectious diseases.

Europe – Major Dominant Countries in the Biologics Market

• Germany: Germany will hold USD 18,720 million in 2025, securing 20% share and a CAGR of 9.43%, underpinned by cutting-edge biopharmaceutical research and production capacity.
• France: France’s biologics market is forecasted at USD 14,040 million in 2025, representing 15% share and a CAGR of 9.43%, driven by early adoption of monoclonal antibodies and advanced vaccines.
• United Kingdom: The United Kingdom will reach USD 12,168 million in 2025, making up 13% share and a CAGR of 9.43%, backed by a thriving life sciences ecosystem and biologics innovation.
• Italy: Italy will capture USD 9,360 million in 2025, representing 10% share and a CAGR of 9.43%, supported by high biologics usage in chronic disease management.
• Spain: Spain’s biologics market will achieve USD 8,424 million in 2025, holding 9% share and a CAGR of 9.43%, aided by national healthcare funding for biologics-based therapies.

ASIA-PACIFIC

Asia-Pacific is forecast to account for approximately USD 247.85 million in biologic demand in 2025, or 27 percent of the global market. The region has approved 80 mAbs, 60 vaccines, 30 recombinant proteins, 10 cellular therapies, and 4 gene-based biologics across major markets including China, Japan, India, South Korea, and Singapore.

The Asia biologics market will account for approximately USD 74,880 million in 2025, translating to 24% share of the global market, propelled by rapid expansion in biomanufacturing capacity, rising prevalence of chronic diseases, and increasing government support for biotechnology innovation..

Asia – Major Dominant Countries in the Biologics Market

• China: China will lead with USD 29,952 million in 2025, commanding 40% share of the Asian market and a CAGR of 9.43%, driven by rapid domestic biologics production and large-scale vaccination programs.
• Japan: Japan’s biologics market will be USD 14,976 million in 2025, representing 20% share and a CAGR of 9.43%, supported by strong innovation in biosimilars and gene-based biologics.
• India: India will secure USD 8,985 million in 2025, about 12% share and a CAGR of 9.43%, driven by affordable biologics manufacturing and growing export markets.
• South Korea: South Korea’s biologics market will reach USD 8,236 million in 2025, representing 11% share and a CAGR of 9.43%, supported by government funding in biopharma clusters.
• Australia: Australia will hold USD 6,740 million in 2025, making up 9% share and a CAGR of 9.43%, driven by high adoption rates in oncology and autoimmune treatment segments.

MIDDLE EAST & AFRICA

Middle East & Africa’s biologics market is estimated at USD 110.15 million, representing 12 percent of global demand. It includes 15 mAbs, 10 vaccines, 5 recombinant proteins, 2 cellular biologics, and 1 gene therapy approved or in advanced development.

The Middle East and Africa biologics market will hold an estimated USD 18,720 million in 2025, representing 6% share of the global market, supported by growing healthcare investments, increasing biologics imports, and the gradual establishment of regional biotechnology hubs.

Middle East and Africa – Major Dominant Countries in the Biologics Market

• Saudi Arabia: Saudi Arabia will hold USD 4,680 million in 2025, capturing 25% share of the regional market and a CAGR of 9.43%, driven by state healthcare reforms and biologics adoption.
• United Arab Emirates: The UAE will achieve USD 3,744 million in 2025, representing 20% share and a CAGR of 9.43%, supported by a fast-growing private healthcare sector.
• South Africa: South Africa’s biologics market will be USD 2,808 million in 2025, making up 15% share and a CAGR of 9.43%, backed by national vaccination campaigns and targeted biologics therapies.
• Egypt: Egypt will secure USD 1,872 million in 2025, representing 10% share and a CAGR of 9.43%, aided by biologics imports and an expanding pharmaceutical base.
• Nigeria: Nigeria will hold USD 1,497 million in 2025, corresponding to 8% share and a CAGR of 9.43%, supported by improved healthcare access and foreign investment in biologics distribution.

List of Top Biologics Companies

• Biogen Idec
• Johnson & Johnson
• Amgen
• Takeda
• AbbVie
• AstraZeneca
• Roche
• Eli Lilly
• Merck
• Novo Nordisk
• Bayer
• GlaxoSmithKline
• Catalent
• Novartis
• Bristol-Myers Squibb
• Sanofi

Roche: is estimated to maintain the leading position with about 25 percent of global biologics approvals and over 50 products active worldwide.

Johnson & Johnson: follows with approximately 20 percent share, delivering over 40 biologic therapies across multiple application areas.

Investment Analysis and Opportunities

The Biologics Market Opportunities section reveals strategic investment trends. In 2024, over 50 new biologic approval targets entered late-stage trials, including 20 mAbs, 8 vaccines, and 5 gene therapies. Investments in manufacturing expanded significantly: 15 new biologics production facilities launched across North America, Europe, and Asia-Pacific.

New Product Development

The Biologics Market Research Report spotlights innovation across therapy types. In 2025, 3 new bispecific antibodies were approved — including mosunetuzumab for lymphoma and linvoseltamab for multiple myeloma. There were 5 novel gene therapy products entering the market, focusing on rare diseases like muscular dystrophy and inherited metabolic disorders.

Five Recent Developments

• 2023 – FDA approved 12 new monoclonal antibodies, marking the highest annual mAb approval count.
• 2023 – The FDA cleared 40 biosimilars, with 50 percent launched commercially — signaling biosimilar momentum.
• 2024 – The bispecific antibody mosunetuzumab received first-in-class approval in EU and US for lymphoma, adding to biologics toolkit.
• 2025 – Linvoseltamab received FDA accelerated approval in July 2025 for relapsed multiple myeloma, advancing bispecific therapy usage.
• 2025 – 60 new biologic R&D facilities were commissioned globally, including 15 in Asia-Pacific, bolstering manufacturing capacity.

Report Coverage of Biological Market

The Biologics Market Report spans approximately 220 pages, featuring 30 tables, 40 charts, and 20 case studies. It covers global and regional metrics, including North America, Europe, Asia-Pacific, and Middle East & Africa, with 15 country profiles such as the US, Germany, China, Japan, India, UK, Saudi Arabia, and UAE.

Biologics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 341422.89 Million in 2026
Market Size Value By	USD 768340.91 Million by 2035
Growth Rate	CAGR of 9.43% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Monoclonal Antibodies Vaccines Recombinant Hormones/Proteins Cellular Based Biologics Gene Based Biologics By Application : Oncology Infectious Diseases Immunology Autoimmune Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample